Learn more

KNOELL HANS FORSCHUNG EV

Overview
  • Total Patents
    117
About

KNOELL HANS FORSCHUNG EV has a total of 117 patent applications. Its first patent ever was published in 1984. It filed its patents most often in Germany, WIPO (World Intellectual Property Organization) and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals, biotechnology and organic fine chemistry are UNIV CHICAGO, UNIV ZARAGOZA and CELLS FOR CELLS S A.

Patent filings per year

Chart showing KNOELL HANS FORSCHUNG EVs patent filings per year from 1900 to 2020

Top inventors

# Name Total Patents
#1 Mueller Peter-Juergen 26
#2 Haertl Albert 22
#3 Ozegowski Joerg-Hermann 14
#4 Schlegel Brigitte 13
#5 Moellmann Ute 11
#6 Graefe Udo 10
#7 Graefe Udo Prof Dr 9
#8 Roth Martin 8
#9 Dahse Hans-Martin 8
#10 Hertel Waltraud 8

Latest patents

Publication Filing date Title
EP2144933A2 Anti-amyloid antibodies and their use in diagnosis and therapy of amyloid diseases
WO2005030976A2 Method for producing a carotinoid-containing biomass
DE102004046616A1 Active pharmaceutical ingredient for the treatment of hospital acquired infection with selected nucleic acid sequence
DE102004046142A1 New selective active substances for the treatment of diseases caused by mycobacteria, process for their preparation and their use
DE102004040014A1 Aureonitriles, process for their preparation and their use
DE102004031999A1 Topical compositions with hyaluronate lyase inhibitory activity, e.g. useful as skin care and cleansing products, comprises carboxy-functional lanostanoids
DE102004020081A1 Formulation having cyclooxygenase inhibiting activity, useful e.g. as antioxidants and to treat pain, liver cirrhosis and Parkinson's disease, comprises components or extracts of Byrsocarpus coccineus and Diodia scandens plants
DE102004018971A1 Microfluidic apparatus producing micro-flows through magnetohydrodynamic principles, subjects electrolyte fluid volume to magnetic and electrical fields
DE102004010219A1 HKI10311129, new antibiotic, process for its preparation and pharmaceutical compositions containing HKI10311129
DE102004008319A1 Continuous one-dimensional solid-phase reactor system
DE10349512A1 Use of 1,4-naphthoquinone derivatives as inhibitors of aspartyl protease, for treatment of infection by Candida or human immune deficiency virus
DE10349511A1 Using fungal naphthopyran-8,9-diones as inhibitors of aspartyl protease, useful for treatment of infection by Candida or human immune deficiency virus
DE10335447A1 amino oxidase
EP1502959A1 A procedure for the creation and use of DNA-recognition element libraries in vivo in relation to gene expression
WO2004110479A1 Hyaluronate lyase-containing agent for treating acute myocardial infarction or symptoms thereof and for the treatment of postinfarction myocarditis and myocardial ischaemia
DE10322893A1 Equipment for microtechnological structuring of fluids used in analytical or combinatorial biology or chemistry, has dosing, splitting and fusion devices in fluid pathway
DE10322942A1 Device for positioning and discharging fluid compartments embedded in the separation medium
DE10310145A1 New but-2-yl-1,4-benzoquinone derivatives, useful for treating viral diseases, especially human T-cell leukemia, obtained by culturing Malbranchea cinnamonea
DE10309866A1 Screening compounds for antifungal activity, particularly against Candida albicans, from their ability to alter expression or activity of fungal homologs of the Wiskott-Aldrich syndrome protein
DE10306075A1 New 2,3-dialkyl-5-hydroxy-benzofuran derivatives, are antioxidants useful for treating e.g. inflammatory and autoimmune diseases, prepared by fermenting Malbranchea cinnamomea HKI 0286